8 Biostatistics Companies for Clinical Trials in 2026

A clinical biostatistics provider designs the statistical framework a trial runs on and turns raw study data into the analyses, tables, and submission-ready datasets that regulators require, work that spans trial design, statistical programming in SAS or R, and CDISC-standard SDTM and ADaM dataset creation. This kind of biostatistics service ranges from small specialist firms built entirely around statisticians and programmers, to technology companies pairing data platforms with biometrics expertise, to functional service provider (FSP) teams that embed directly within a sponsor's own systems and processes.

The biostatistics companies below are listed in no particular order. Between them, these companies and providers cover project-based statistical consulting, embedded FSP biometrics teams, AI-powered clinical data and statistics platforms, and specialist expertise in areas like oncology, rare disease, and health economics.

ClinStat

ClinStat has operated as an independent CRO near Cologne, Germany since 2006, building an integrated biostatistics, statistical programming, and health economics and outcomes research (HEOR) practice alongside data management and medical writing services. The company's team draws on backgrounds spanning biometrics, psychometrics, epidemiology, and health economics, supporting pre-clinical through Phase IV studies as well as post-marketing and observational research. ClinStat's HEOR and market access work includes preparing health economic analyses for HTA dossiers, including Germany's early benefit dossier process under the AMNOG framework, a specialized regulatory requirement distinct from clinical trial statistics alone. The company has remained a small, specialized operation with roughly a dozen employees, positioning itself as a preferred CRO for select pharmaceutical clients rather than pursuing broad scale.

EDETEK

EDETEK built CONFORM, a cloud-based clinical data and informatics platform that connects to more than 75 data sources, standardizes incoming study data to formats like SDTM and ADaM, and prepares it for statistical analysis and regulatory submission. Founded in 2009 and based in Princeton, New Jersey, the company is led by CEO Jian Chen, who previously co-founded and served as CTO of Q-Square Business Intelligence before starting EDETEK. In September 2025, EDETEK launched BioStat.AI, which the company describes as the industry's first unified AI platform combining clinical data management, biostatistics, and statistical programming, built on large language models and predictive analytics layered onto its existing CONFORM and eClinical platforms. EDETEK reports serving more than 100 biopharmaceutical companies across four continents, pairing its technology platform with biostatistics, clinical programming, and medical writing services delivered by its own teams.

Ephicacy Consulting

Ephicacy was founded in 2005 by Ganesh Gopal as a niche provider of biostatistics, statistical programming, and clinical data management services, and has since grown into what the company calls a leading biometrics CRO with operations across North America, India, and Europe. The company reports supporting more than 1,230 projects across more than 100 therapeutic indications over 20-plus years, backed by a 94 percent staff retention rate that lets sponsors work with the same experienced teams across a program's lifecycle. In February 2025, Ephicacy named Tara Gladwell as Chief Executive Officer, bringing nearly three decades of CRO industry experience from her prior role as President of Rho, while founder Gopal transitioned to Chairman and President to focus on strategic growth. Ephicacy's services span data management, statistical programming, biostatistics, DMC support, real-world evidence analytics, and pharmacovigilance, offered through FSP, project-based, or hybrid engagement models.

Innovative Analytics

Innovative Analytics was co-founded in 2003 by Jim, a former Director of Clinical Database Operations at Pharmacia and Director of Experimental Medicine Informatics at Pfizer, alongside Patty Ruppel, who has since retired from day-to-day operations. Based in Kalamazoo, Michigan, the company provides statistical analysis, data management, and medical writing services from protocol design through study report writing, drawing heavily on staff who previously worked at Upjohn, Pharmacia, and Pfizer, all with historical roots in the same Michigan pharmaceutical hub. Innovative Analytics was named among the Michigan 50 Companies to Watch in 2011 by the Michigan Biosciences Organization, recognizing its work supporting clinical drug and device development programs. The company's statistics team includes members with more than 35 years of individual pharmaceutical industry experience, including work on both US and EU regulatory submissions in central nervous system and critical care therapeutic areas.

K3 Innovations

K3-Innovations provides biostatistics and statistical programming, SDTM implementation, and Functional Service Provider (FSP) support to biopharmaceutical and medical device companies, positioning itself as a next-generation CRO built around AI-powered automation and adaptive clinical resourcing. Founded in 2013 and based in New Jersey, the company built a proprietary framework it calls Synergetic Scaling, offering sponsors flexible engagement tiers ranging from light-touch technology oversight to full outsourced statistical programming and biostatistics delivery. K3's services are governed by SOPs compliant with ICH/GCP and FDA 21 CFR Part 11, and the company positions its model as reducing both cost and risk compared with either fully in-house teams or larger, less flexible CRO engagements. The company has built a track record supporting global clinical trials across multiple phases and therapeutic areas for sponsors ranging from small biotechs to larger pharmaceutical companies.

NJS Associates

NJS Associates was founded in 2011 by a group of expert biostatisticians and has grown into a biostatistics-led CRO that has supported more than 100 clinical trials and 10 successful FDA submissions, including NDA and BLA filings. The Bridgewater, New Jersey-based company built its own in-house, oncology-specific proprietary SAS macro system, giving it particular strength in validated oncology investigator assessments alongside broader expertise in CNS, cardiovascular, rare disease, and vaccine trials. NJS offers three engagement models, ranging from full CRO delivery with end-to-end ownership of biostatistics and programming, to embedded Functional Service Provider teams working within a sponsor's own systems and SOPs, to strategic staffing for shorter-term biometrics needs. The company applies adaptive and Bayesian statistical methodologies aimed at optimizing trial speed and efficiency, while maintaining CDISC data standards and FDA compliance across every statistical programming task.

Prometrika

Prometrika was established in January 2003 by a group of former colleagues who had spent a decade collaborating within the drug development division of a mid-sized international pharmaceutical company, initially operating as a functional service provider for data management, biostatistics, and medical writing before adding clinical operations and pharmacovigilance in 2007 to become a full-service CRO. Based in Cambridge, Massachusetts, in the heart of New England's biotechnology cluster, the company has completed more than 20 successful NDA, BLA, and MAA regulatory submissions across its history. Prometrika has built particular depth in rare disease research, having supported more than 85 rare disease studies where its biostatisticians apply specialized methodologies for small sample sizes and combine natural history data with clinical trial results to address the unique challenges these programs present. The company's biostatistics team, averaging 15 years of individual industry experience, also supports Independent Data Monitoring Committees as voting or non-voting statistician members.

Veramed

Veramed operates as what it calls a modern CRO built around statisticians, programmers, and data managers, offering both project-based biostatistics consultancy and larger-scale Functional Service Provider (FSP) engagements that can onboard 100 to 200 full-time employees annually across the UK, US, Europe, India, and Ukraine. Led by CEO Troy McCall, the company was reaccredited as a 3-star Best Companies workplace in November 2025, and positions its people-first culture as a competitive advantage in an industry known for high staff turnover on program teams. Veramed's biostatistics work spans trial design and planning, randomization and blinding, Statistical Analysis Plans, and adaptive and Bayesian design support, and the company has provided independent unblinded statistical support for Data Monitoring Committee deliveries on complex Phase IIb studies with multiple interim analyses. The company also offers legacy clinical trial data conversion to CDISC-compliant formats, helping sponsors bring older or inherited datasets up to current submission standards.

Explore the full Statistical Programming & Biostatistics landscape

The companies above represent a portion of a much larger field.

Diligent's platform includes over 490 Statistical Programming & Biostatistics Vendors, with Vendor qualification data available on demand. Book a demo to see the vendors and qualification reports available on the platform.

This article is intended as an informational overview of vendors operating in this space. Inclusion on this list does not constitute an endorsement, recommendation, or qualification by Diligent.